Industry

Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 SANTA CLARA, Calif.–(BUSINESS WIRE)–$A #BringGreatScienceToLife—Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian … [Read more…]

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a statistically significant improvement in overall survival (OS) and significantly extended time to pain progression in patients treated with Optune Pax Optune Pax is a wearable … [Read more…]

DUBLIN–(BUSINESS WIRE)–Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company. The webcast player and … [Read more…]

The full-service digital pharmacy recorded faster delivery speeds in 2025 and will expand Same-Day Delivery service to nearly 2,000 cities and towns this year, bringing access in new states including Idaho and Massachusetts in 2026 SEATTLE–(BUSINESS WIRE)–Amazon Pharmacy today announced it will expand its Same-Day prescription delivery service to nearly 4,500 U.S. cities and towns … [Read more…]

With 43+ Million Vials Shipped Globally1, XEOMIN® continues to be a leader in the toxin industry RALEIGH, N.C.–(BUSINESS WIRE)–Merz Aesthetics, the world’s largest dedicated medical aesthetics business, celebrates 15 years since its flagship brand XEOMIN® was first approved for aesthetic use by the U.S. Food and Drug Administration (FDA). XEOMIN® is a double-purified neurotoxin, FDA … [Read more…]

– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – Institutional Review Board (IRB) process is underway at multiple world-class DMD clinical trial sites – – PBGENE-DMD is an in vivo gene editing investigational product … [Read more…]

The 2026 Love and Money Benchmark Survey compares 2025 and 2026 data to reveal how financial pressures are increasingly straining Canadian relationships and dating lives year-over-year. CALGARY, Alberta–(BUSINESS WIRE)–As affordability pressures continue to weigh on households across the country, financial stress is taking a growing toll on Canadians’ relationships. According to the 2026 Love and … [Read more…]

Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4 These two new launches … [Read more…]

Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabetes mellitus (T2DM), consistent with that of the GLP-1 receptor agonist class Pharmacokinetic results in this study were comparable with the prior data generated from global Phase 1 clinical studies, supporting potential use of a consistent … [Read more…]

FOSTER CITY, Calif.–(BUSINESS WIRE)–#Dividend–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 3.8% in the company’s quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on … [Read more…]